Global Alpha- Antitrypsin Deficiency Treatment Market Size, Status and Forecast 2020-2026

Global Alpha- Antitrypsin Deficiency Treatment Market Size, Status and Forecast 2020-2026

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
1.4 Market Analysis by Type
1.4.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 CT-2009
1.4.3 POL-6014
1.4.4 ARO-AAT
1.4.5 ALNAAT-02
1.4.6 Others
1.5 Market by Application
1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Alpha- Antitrypsin Deficiency Treatment Market Perspective (2015-2026)
2.2 Alpha- Antitrypsin Deficiency Treatment Growth Trends by Regions
2.2.1 Alpha- Antitrypsin Deficiency Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Alpha- Antitrypsin Deficiency Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter's Five Forces Analysis
2.3.5 Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Alpha- Antitrypsin Deficiency Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Market Size
3.1.1 Global Top Alpha- Antitrypsin Deficiency Treatment Players by Revenue (2015-2020)
3.1.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio
3.2.1 Global Alpha- Antitrypsin Deficiency Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
3.3 Alpha- Antitrypsin Deficiency Treatment Key Players Head office and Area Served
3.4 Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
3.5 Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Alpha- Antitrypsin Deficiency Treatment Historic Market Size by Type (2015-2020)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2021-2026)
5 Alpha- Antitrypsin Deficiency Treatment Breakdown Data by Application (2015-2026)
5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
5.2 Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
6.2 Alpha- Antitrypsin Deficiency Treatment Key Players in North America (2019-2020)
6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
6.4 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
7.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Europe (2019-2020)
7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
7.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
8 China
8.1 China Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
8.2 Alpha- Antitrypsin Deficiency Treatment Key Players in China (2019-2020)
8.3 China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
8.4 China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
9.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Japan (2019-2020)
9.3 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
9.4 Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
10.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
11 India
11.1 India Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
11.2 Alpha- Antitrypsin Deficiency Treatment Key Players in India (2019-2020)
11.3 India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
11.4 India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size (2015-2020)
12.2 Alpha- Antitrypsin Deficiency Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020)
12.4 Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Adverum Biotechnologies, Inc.
13.1.1 Adverum Biotechnologies, Inc. Company Details
13.1.2 Adverum Biotechnologies, Inc. Business Overview and Its Total Revenue
13.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.1.4 Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020))
13.1.5 Adverum Biotechnologies, Inc. Recent Development
13.2 Alnylam Pharmaceuticals, Inc.
13.2.1 Alnylam Pharmaceuticals, Inc. Company Details
13.2.2 Alnylam Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.2.4 Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.2.5 Alnylam Pharmaceuticals, Inc. Recent Development
13.3 Applied Genetic Technologies Corporation
13.3.1 Applied Genetic Technologies Corporation Company Details
13.3.2 Applied Genetic Technologies Corporation Business Overview and Its Total Revenue
13.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
13.3.4 Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.3.5 Applied Genetic Technologies Corporation Recent Development
13.4 Arrowhead Pharmaceuticals, Inc.
13.4.1 Arrowhead Pharmaceuticals, Inc. Company Details
13.4.2 Arrowhead Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.4.4 Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.4.5 Arrowhead Pharmaceuticals, Inc. Recent Development
13.5 Carolus Therapeutics, Inc.
13.5.1 Carolus Therapeutics, Inc. Company Details
13.5.2 Carolus Therapeutics, Inc. Business Overview and Its Total Revenue
13.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.5.4 Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.5.5 Carolus Therapeutics, Inc. Recent Development
13.6 Cevec Pharmaceuticals GmbH
13.6.1 Cevec Pharmaceuticals GmbH Company Details
13.6.2 Cevec Pharmaceuticals GmbH Business Overview and Its Total Revenue
13.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Introduction
13.6.4 Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.6.5 Cevec Pharmaceuticals GmbH Recent Development
13.7 Dicerna Pharmaceuticals, Inc.
13.7.1 Dicerna Pharmaceuticals, Inc. Company Details
13.7.2 Dicerna Pharmaceuticals, Inc. Business Overview and Its Total Revenue
13.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.7.4 Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.7.5 Dicerna Pharmaceuticals, Inc. Recent Development
13.8 Digna Biotech, S.L.
13.8.1 Digna Biotech, S.L. Company Details
13.8.2 Digna Biotech, S.L. Business Overview and Its Total Revenue
13.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Introduction
13.8.4 Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.8.5 Digna Biotech, S.L. Recent Development
13.9 Editas Medicine, Inc.
13.9.1 Editas Medicine, Inc. Company Details
13.9.2 Editas Medicine, Inc. Business Overview and Its Total Revenue
13.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
13.9.4 Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.9.5 Editas Medicine, Inc. Recent Development
13.10 Grifols, S.A.
13.10.1 Grifols, S.A. Company Details
13.10.2 Grifols, S.A. Business Overview and Its Total Revenue
13.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Introduction
13.10.4 Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
13.10.5 Grifols, S.A. Recent Development
13.11 Inhibrx
10.11.1 Inhibrx Company Details
10.11.2 Inhibrx Business Overview and Its Total Revenue
10.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Introduction
10.11.4 Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.11.5 Inhibrx Recent Development
13.12 Intellia Therapeutics, Inc.
10.12.1 Intellia Therapeutics, Inc. Company Details
10.12.2 Intellia Therapeutics, Inc. Business Overview and Its Total Revenue
10.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.12.4 Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.12.5 Intellia Therapeutics, Inc. Recent Development
13.13 International Stem Cell Corporation
10.13.1 International Stem Cell Corporation Company Details
10.13.2 International Stem Cell Corporation Business Overview and Its Total Revenue
10.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Introduction
10.13.4 International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.13.5 International Stem Cell Corporation Recent Development
13.14 Ionis Pharmaceuticals, Inc.
10.14.1 Ionis Pharmaceuticals, Inc. Company Details
10.14.2 Ionis Pharmaceuticals, Inc. Business Overview and Its Total Revenue
10.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.14.4 Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.14.5 Ionis Pharmaceuticals, Inc. Recent Development
13.15 Kamada Ltd.
10.15.1 Kamada Ltd. Company Details
10.15.2 Kamada Ltd. Business Overview and Its Total Revenue
10.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
10.15.4 Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.15.5 Kamada Ltd. Recent Development
13.16 Polyphor Ltd.
10.16.1 Polyphor Ltd. Company Details
10.16.2 Polyphor Ltd. Business Overview and Its Total Revenue
10.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Introduction
10.16.4 Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.16.5 Polyphor Ltd. Recent Development
13.17 ProMetic Life Sciences Inc.
10.17.1 ProMetic Life Sciences Inc. Company Details
10.17.2 ProMetic Life Sciences Inc. Business Overview and Its Total Revenue
10.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.17.4 ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.17.5 ProMetic Life Sciences Inc. Recent Development
13.18 rEVO Biologics, Inc.
10.18.1 rEVO Biologics, Inc. Company Details
10.18.2 rEVO Biologics, Inc. Business Overview and Its Total Revenue
10.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.18.4 rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.18.5 rEVO Biologics, Inc. Recent Development
13.19 Sangamo BioSciences, Inc.
10.19.1 Sangamo BioSciences, Inc. Company Details
10.19.2 Sangamo BioSciences, Inc. Business Overview and Its Total Revenue
10.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Introduction
10.19.4 Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
10.19.5 Sangamo BioSciences, Inc. Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
List of Tables
Table 1. Alpha- Antitrypsin Deficiency Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha- Antitrypsin Deficiency Treatment Revenue
Table 3. Ranking of Global Top Alpha- Antitrypsin Deficiency Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of CT-2009
Table 6. Key Players of POL-6014
Table 7. Key Players of ARO-AAT
Table 8. Key Players of ALNAAT-02
Table 9. Key Players of Others
Table 10. Global Alpha- Antitrypsin Deficiency Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2015-2020)
Table 14. Global Alpha- Antitrypsin Deficiency Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Alpha- Antitrypsin Deficiency Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Alpha- Antitrypsin Deficiency Treatment Players
Table 21. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players (2015-2020)
Table 23. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019)
Table 24. Global Alpha- Antitrypsin Deficiency Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Alpha- Antitrypsin Deficiency Treatment Product Solution and Service
Table 27. Date of Enter into Alpha- Antitrypsin Deficiency Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Type (2015-2020)
Table 31. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2015-2020)
Table 33. Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Alpha- Antitrypsin Deficiency Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 37. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 39. North America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 43. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 45. Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 49. China Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 51. China Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 55. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 57. Japan Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 61. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 67. India Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 69. India Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Alpha- Antitrypsin Deficiency Treatment Market Share (2019-2020)
Table 73. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Share by Application (2015-2020)
Table 77. Adverum Biotechnologies, Inc. Company Details
Table 78. Adverum Biotechnologies, Inc. Business Overview
Table 79. Adverum Biotechnologies, Inc. Product
Table 80. Adverum Biotechnologies, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 81. Adverum Biotechnologies, Inc. Recent Development
Table 82. Alnylam Pharmaceuticals, Inc. Company Details
Table 83. Alnylam Pharmaceuticals, Inc. Business Overview
Table 84. Alnylam Pharmaceuticals, Inc. Product
Table 85. Alnylam Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 86. Alnylam Pharmaceuticals, Inc. Recent Development
Table 87. Applied Genetic Technologies Corporation Company Details
Table 88. Applied Genetic Technologies Corporation Business Overview
Table 89. Applied Genetic Technologies Corporation Product
Table 90. Applied Genetic Technologies Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 91. Applied Genetic Technologies Corporation Recent Development
Table 92. Arrowhead Pharmaceuticals, Inc. Company Details
Table 93. Arrowhead Pharmaceuticals, Inc. Business Overview
Table 94. Arrowhead Pharmaceuticals, Inc. Product
Table 95. Arrowhead Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 96. Arrowhead Pharmaceuticals, Inc. Recent Development
Table 97. Carolus Therapeutics, Inc. Company Details
Table 98. Carolus Therapeutics, Inc. Business Overview
Table 99. Carolus Therapeutics, Inc. Product
Table 100. Carolus Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 101. Carolus Therapeutics, Inc. Recent Development
Table 102. Cevec Pharmaceuticals GmbH Company Details
Table 103. Cevec Pharmaceuticals GmbH Business Overview
Table 104. Cevec Pharmaceuticals GmbH Product
Table 105. Cevec Pharmaceuticals GmbH Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 106. Cevec Pharmaceuticals GmbH Recent Development
Table 107. Dicerna Pharmaceuticals, Inc. Company Details
Table 108. Dicerna Pharmaceuticals, Inc. Business Overview
Table 109. Dicerna Pharmaceuticals, Inc. Product
Table 110. Dicerna Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 111. Dicerna Pharmaceuticals, Inc. Recent Development
Table 112. Digna Biotech, S.L. Business Overview
Table 113. Digna Biotech, S.L. Product
Table 114. Digna Biotech, S.L. Company Details
Table 115. Digna Biotech, S.L. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 116. Digna Biotech, S.L. Recent Development
Table 117. Editas Medicine, Inc. Company Details
Table 118. Editas Medicine, Inc. Business Overview
Table 119. Editas Medicine, Inc. Product
Table 120. Editas Medicine, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 121. Editas Medicine, Inc. Recent Development
Table 122. Grifols, S.A. Company Details
Table 123. Grifols, S.A. Business Overview
Table 124. Grifols, S.A. Product
Table 125. Grifols, S.A. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 126. Grifols, S.A. Recent Development
Table 127. Inhibrx Company Details
Table 128. Inhibrx Business Overview
Table 129. Inhibrx Product
Table 130. Inhibrx Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 131. Inhibrx Recent Development
Table 132. Intellia Therapeutics, Inc. Company Details
Table 133. Intellia Therapeutics, Inc. Business Overview
Table 134. Intellia Therapeutics, Inc. Product
Table 135. Intellia Therapeutics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 136. Intellia Therapeutics, Inc. Recent Development
Table 137. International Stem Cell Corporation Company Details
Table 138. International Stem Cell Corporation Business Overview
Table 139. International Stem Cell Corporation Product
Table 140. International Stem Cell Corporation Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 141. International Stem Cell Corporation Recent Development
Table 142. Ionis Pharmaceuticals, Inc. Company Details
Table 143. Ionis Pharmaceuticals, Inc. Business Overview
Table 144. Ionis Pharmaceuticals, Inc. Product
Table 145. Ionis Pharmaceuticals, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 146. Ionis Pharmaceuticals, Inc. Recent Development
Table 147. Kamada Ltd. Company Details
Table 148. Kamada Ltd. Business Overview
Table 149. Kamada Ltd. Product
Table 150. Kamada Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 151. Kamada Ltd. Recent Development
Table 152. Polyphor Ltd. Company Details
Table 153. Polyphor Ltd. Business Overview
Table 154. Polyphor Ltd. Product
Table 155. Polyphor Ltd. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 156. Polyphor Ltd. Recent Development
Table 157. ProMetic Life Sciences Inc. Company Details
Table 158. ProMetic Life Sciences Inc. Business Overview
Table 159. ProMetic Life Sciences Inc. Product
Table 160. ProMetic Life Sciences Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 161. ProMetic Life Sciences Inc. Recent Development
Table 162. rEVO Biologics, Inc. Company Details
Table 163. rEVO Biologics, Inc. Business Overview
Table 164. rEVO Biologics, Inc. Product
Table 165. rEVO Biologics, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 166. rEVO Biologics, Inc. Recent Development
Table 167. Sangamo BioSciences, Inc. Company Details
Table 168. Sangamo BioSciences, Inc. Business Overview
Table 169. Sangamo BioSciences, Inc. Product
Table 170. Sangamo BioSciences, Inc. Revenue in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020) (Million US$)
Table 171. Sangamo BioSciences, Inc. Recent Development
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Type: 2020 VS 2026
Figure 2. CT-2009 Features
Figure 3. POL-6014 Features
Figure 4. ARO-AAT Features
Figure 5. ALNAAT-02 Features
Figure 6. Others Features
Figure 7. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Application: 2020 VS 2026
Figure 8. Clinic Case Studies
Figure 9. Hospital Case Studies
Figure 10. Others Case Studies
Figure 11. Alpha- Antitrypsin Deficiency Treatment Report Years Considered
Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Alpha- Antitrypsin Deficiency Treatment Market Share by Players in 2019
Figure 17. Global Top Alpha- Antitrypsin Deficiency Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha- Antitrypsin Deficiency Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Alpha- Antitrypsin Deficiency Treatment Revenue in 2019
Figure 19. North America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Alpha- Antitrypsin Deficiency Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Adverum Biotechnologies, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Adverum Biotechnologies, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 28. Alnylam Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Alnylam Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 30. Applied Genetic Technologies Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Applied Genetic Technologies Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 32. Arrowhead Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Arrowhead Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 34. Carolus Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Carolus Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 36. Cevec Pharmaceuticals GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Cevec Pharmaceuticals GmbH Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 38. Dicerna Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Dicerna Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 40. Digna Biotech, S.L. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Digna Biotech, S.L. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 42. Editas Medicine, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Editas Medicine, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 44. Grifols, S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Grifols, S.A. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 46. Inhibrx Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Inhibrx Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 48. Intellia Therapeutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Intellia Therapeutics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 50. International Stem Cell Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. International Stem Cell Corporation Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 52. Ionis Pharmaceuticals, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Ionis Pharmaceuticals, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 54. Kamada Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Kamada Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 56. Polyphor Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Polyphor Ltd. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 58. ProMetic Life Sciences Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. ProMetic Life Sciences Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 60. rEVO Biologics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. rEVO Biologics, Inc. Revenue Growth Rate in Alpha- Antitrypsin Deficiency Treatment Business (2015-2020)
Figure 62. Sangamo BioSciences, Inc. T

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029

Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118

The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......

Global Non-imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95

The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Imaging Diagnostic Catheter Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90

The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......

Global PCR Equipment Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77

The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......

Global Disposable Sterile Syringes and Needles Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109

The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......

Global Orthopaedic Power Tools Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......

Global Cerebrospinal Fluid Management Devices Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......

Global CAD & CAM Milling Burs Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79

The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......

Global Artificial Teeth Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98

The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs